Pyxis Oncology Q3 2024 Update

Ticker: PYXS · Form: 10-Q · Filed: 2024-11-12T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, royalty sale, licensing, collaboration

TL;DR

Pyxis Oncology Q3 10-Q: $10M Novartis deal closed, Pfizer/Apexigen collaborations ongoing.

AI Summary

Pyxis Oncology, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and operational updates. Key events include the sale of royalty rights to Novartis for $10 million on March 25, 2024, and ongoing activities related to its Pfizer license agreement and Apexigen Inc. collaboration.

Why It Matters

This filing provides insight into Pyxis Oncology's financial health and strategic partnerships, which are crucial for its drug development pipeline and future growth prospects.

Risk Assessment

Risk Level: medium — The company is in the pharmaceutical development stage, which inherently carries high risks related to clinical trials, regulatory approvals, and market adoption.

Key Numbers

Key Players & Entities

FAQ

What were the total operating expenses for the nine months ended September 30, 2024?

The filing indicates that General and Administrative Expense for the nine months ended September 30, 2023, was a component, but specific total operating expenses for the 2024 period are not detailed in the provided snippet.

What is the status of the Pfizer License Agreement?

The filing references the Pfizer License Agreement, which was entered into around March 2021, indicating ongoing activities or terms related to it.

What was the nature of the transaction with Novartis on March 25, 2024?

Pyxis Oncology entered into the Fourth Amendment Settlement Agreement and Royalty Purchase Agreement with Novartis, resulting in the sale of royalty rights for $10 million.

Does Pyxis Oncology have any at-the-market offering programs?

Yes, the filing mentions an 'At The Market Offering Program' in relation to common stock during the period from July 1, 2024, to September 30, 2024.

What is the company's fiscal year end?

Pyxis Oncology's fiscal year ends on December 31.

Filing Stats: 4,394 words · 18 min read · ~15 pages · Grade level 17.1 · Accepted 2024-11-12 07:43:31

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2024 and 2023 4 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2024 and 2023 5 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2024 and 2023 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.

Controls and Procedures

Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.

Legal Proceedings

Legal Proceedings 27 Item 1A.

Risk Factors

Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 75 Item 3. Defaults Upon Senior Securities 75 Item 4. Mine Safety Disclosures 75 Item 5. Other Information 75 Item 6. Exhibits 76

Signatures

Signatures 77 i SUMMA RY RISK FACTORS You should consider carefully the risks described under "Risk Factors" in Part II, Item 1A of this Quarterly Report on Form 10-Q. References to "Pyxis Oncology," the "Company," "we," "us," and "our" in this section titled "Summary Risk Factors" refer to Pyxis Oncology, Inc. and its wholly owned subsidiaries. A summary of the risks that could materially and adversely affect our business, financial condition, operating results and prospects include the following: We are a clinical stage biopharmaceutical company with a limited operating history and have incurred significant losses since our inception. We expect to incur losses over at least the next several years and may never achieve or maintain profitability. We will require substantial additional capital to finance our operations, obtain regulatory approval for our product candidates and commercialize our product candidates. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts. We are heavily dependent on the success of PYX-201 and PYX-106, which are in the early stages of development, and if PYX-201 and/or PYX-106 are not successful in clinical trials or do not receive regulatory approval or licensure or are not successfully commercialized, our business will be materially and adversely affected. Our product candidates may fail in development or suffer delays that materially and adversely affect their commercial viability. If we or our existing or future collaborators are unable to initiate and complete clinical development of, obtain regulatory approval or licensure for or commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. Our preclinical studies and clinical trials may fail to demonstrate adequately the safety, purity and p

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PYXIS ONCOLO GY, INC. Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) (Unaudited) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 12,056 $ 9,664 Marketable debt securities, short-term 132,762 109,634 Restricted cash 1,472 1,472 Prepaid expenses and other current assets 2,578 3,834 Total current assets 148,868 124,604 Property and equipment, net 10,396 11,872 Intangible assets, net 23,619 24,308 Right-of-use asset 12,428 12,942 Total assets $ 195,311 $ 173,726 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 4,870 $ 3,896 Accrued expenses and other current liabilities 14,057 12,971 Operating lease liabilities, current portion 1,393 1,232 Deferred revenues — 7,660 Total current liabilities 20,320 25,759 Operating lease liabilities, net of current portion 19,030 20,099 Financing lease liabilities, net of current portion 117 — Deferred tax liability, net 2,164 2,164 Total liabilities 41,631 48,022 Commitments and contingencies (Note 14) Stockholders' equity: Preferred stock, par value $ 0.001 per share, 10,000,000 shares authorized; zero shares issued and outstanding — — Common stock, par value $ 0.001 per share; 190,000,000 shares authorized; 59,449,998 and 44,754,853 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively. 59 45 Additional paid-in capital 481,255 411,821 Accumulated other comprehensive income 351 63 Accumulated deficit ( 327,985 ) ( 286,225 ) Total stockholders' equity 153,680 125,704 Total liabilities and stockholders' equity $ 195,311 $ 173,726 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 PYXIS ONCOLOGY, INC. Condens

View on Read The Filing